Kadmon Holdings, Inc. logo
Kadmon Holdings, Inc. KDMN

Kadmon Holdings, Inc. Revenue | KDMN

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Kadmon Holdings, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
8.29 M 5.1 M 1.4 M 12.3 M 26.1 M 35.7 M 95 M - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
95 M 1.4 M 26.3 M

References

  1. Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer Revenue Price % 24h Market Cap Country
Kiniksa Pharmaceuticals, Ltd. Kiniksa Pharmaceuticals, Ltd.
KNSA
678 M $ 76.31 0.69 % $ 5.66 B usaUSA
Karyopharm Therapeutics Karyopharm Therapeutics
KPTI
146 M $ 0.67 1.51 % $ 7.33 K usaUSA
Keros Therapeutics Keros Therapeutics
KROS
244 M $ 11.52 1.41 % $ 429 M usaUSA
Krystal Biotech Krystal Biotech
KRYS
389 M $ 334.85 3.9 % $ 9.69 B usaUSA
Kura Oncology Kura Oncology
KURA
67.5 M $ 10.62 0.09 % $ 931 M usaUSA
Kymera Therapeutics Kymera Therapeutics
KYMR
39.2 M $ 109.85 2.29 % $ 9.28 B usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
42 K $ 9.35 0.86 % $ 143 M australiaAustralia
Lineage Cell Therapeutics Lineage Cell Therapeutics
LCTX
14.6 M $ 0.93 2.73 % $ 214 M usaUSA
Legend Biotech Corporation Legend Biotech Corporation
LEGN
627 M $ 18.77 1.1 % $ 6.92 B usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
268 M $ 306.77 1.26 % $ 5.93 B usaUSA
Longeveron Longeveron
LGVN
1.2 M $ 2.51 0.39 % $ 44.1 B usaUSA
Eli Lilly and Company Eli Lilly and Company
LLY
65.2 B $ 1 143.12 0.02 % $ 1.03 T usaUSA
Lipocine Lipocine
LPCN
1.98 M $ 2.07 0.98 % $ 11.3 M usaUSA
Liquidia Corporation Liquidia Corporation
LQDA
158 M $ 27.64 2.32 % $ 2.38 B usaUSA
Lexicon Pharmaceuticals Lexicon Pharmaceuticals
LXRX
49.8 M $ 1.74 0.82 % $ 632 M usaUSA
Seres Therapeutics Seres Therapeutics
MCRB
789 K $ 2.85 0.34 % $ 25.2 M usaUSA
Madrigal Pharmaceuticals Madrigal Pharmaceuticals
MDGL
958 M $ 493.62 0.1 % $ 11.1 B usaUSA
MediWound Ltd. MediWound Ltd.
MDWD
21.8 M $ 13.51 0.22 % $ 368 M israelIsrael
Mesoblast Limited Mesoblast Limited
MESO
17.2 M $ 14.22 0.99 % $ 17.2 B australiaAustralia
MacroGenics MacroGenics
MGNX
150 M $ 3.77 5.31 % $ 238 M usaUSA
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
81.4 M $ 10.92 1.2 % $ 878 M usaUSA
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
521 M $ 81.43 0.07 % $ 4.09 B usaUSA
MannKind Corporation MannKind Corporation
MNKD
349 M $ 3.82 0.53 % $ 1.17 B usaUSA
MediciNova MediciNova
MNOV
410 K $ 1.76 0.28 % $ 86.4 M usaUSA
Mereo BioPharma Group plc Mereo BioPharma Group plc
MREO
36.5 M $ 0.39 2.16 % $ 311 M britainBritain
Merck & Co. Merck & Co.
MRK
65 B $ 139.54 0.34 % $ 349 B usaUSA
Marker Therapeutics Marker Therapeutics
MRKR
3.55 M $ 1.06 0.95 % $ 16.2 M usaUSA
Moderna Moderna
MRNA
1.94 B $ 203.21 6.95 % $ 79 B usaUSA
Maravai LifeSciences Holdings Maravai LifeSciences Holdings
MRVI
186 M $ 8.52 7.85 % $ 1.23 B usaUSA
Matinas BioPharma Holdings Matinas BioPharma Holdings
MTNB
1.1 M $ 2.82 6.82 % $ 15.4 M usaUSA
RAPT Therapeutics RAPT Therapeutics
RAPT
1.53 M - - $ 2.36 B usaUSA
Neurocrine Biosciences Neurocrine Biosciences
NBIX
2.86 B $ 144.21 0.72 % $ 14.3 B usaUSA
Nanobiotix S.A. Nanobiotix S.A.
NBTX
32.6 M $ 25.1 0.16 % $ 1.2 T franceFrance
Minerva Neurosciences Minerva Neurosciences
NERV
41.2 M $ 3.32 1.22 % $ 28.1 M usaUSA
Nektar Therapeutics Nektar Therapeutics
NKTR
55.2 M $ 42.22 2.2 % $ 712 M usaUSA
Nkarta Nkarta
NKTX
115 K $ 2.53 0.59 % $ 187 M usaUSA
Nurix Therapeutics Nurix Therapeutics
NRIX
84 M $ 22.88 0.09 % $ 1.98 B usaUSA
Nuvation Bio Nuvation Bio
NUVB
62.9 M $ 4.95 1.07 % $ 1.69 B usaUSA
Novavax Novavax
NVAX
1.12 B $ 12.56 20.08 % $ 2.03 B usaUSA
Novo Nordisk A/S Novo Nordisk A/S
NVO
309 B $ 37.54 0.59 % $ 167 B danmarkDanmark
Novartis AG Novartis AG
NVS
49.9 B $ 140.93 0.01 % $ 273 B schweizSchweiz